MaxCyte Board Change: Honoring Art Mandell's Legacy
MaxCyte, Inc. (NASDAQ: MXCT), a pioneering company in cell engineering technologies, recently announced that long-serving board member Art Mandell has chosen to retire from his position on the Board of Directors effective December 31, 2024. Mr. Mandell's influence on the company began in 2006, positioning him as a key figure in its innovative growth.
Significant Achievements During Mandell's Tenure
Throughout his time on the Board, Mandell has witnessed and contributed to several remarkable milestones at MaxCyte. This includes the company’s successful initial public offering on the UK AIM exchange and its listing on the NASDAQ. Under his guidance, MaxCyte also launched its flagship ExPERT™ platform, which has proven essential in advancing cell and gene therapy. The company has amassed an impressive portfolio, securing 29 Strategic Platform Licenses and backing the first FDA-approved CRISPR edited non-viral cell therapy in the industry.
Expressions of Gratitude
Richard Douglas, chairman of the Board, expressed heartfelt thanks, stating, "We are deeply grateful for Art's exceptional leadership, scientific insights, and valuable contributions over the years." Mr. Mandell’s vision and strategic input have undeniably helped position MaxCyte as a frontrunner in the competitive field of cell engineering.
Art Mandell's Reflection on His Role
Mr. Mandell shared his sentiments regarding his time with MaxCyte, describing it as a privilege to serve on the Board. He expressed pride in the achievements the company has accomplished and confidence in its future ventures, particularly in delivering innovative solutions that support the development of groundbreaking cell and gene therapies.
A Glimpse into MaxCyte's Future
As MaxCyte moves forward with only nine remaining directors following Mandell's departure, the company remains focused on its mission to facilitate advanced cell therapies. With over 25 years of experience, MaxCyte has been at the forefront of cell engineering, equipping partners with cutting-edge tools and support to transform healthcare outcomes. The ExPERT™ platform, characterized by Flow Electroporation technology, supports the evolving cell therapy market and spans the entire lifecycle—from research through to commercialization.
MaxCyte’s Commitment to Innovation
The ExPERT family is not merely a technology platform; it consists of various products such as the ATx™, STx™, GTx™, and VLx™ instruments, along with proprietary processing assemblies and software protocols. MaxCyte's dedication to enhancing cell therapy aligns perfectly with the rising demand for effective and novel medicinal solutions in the healthcare landscape.
Maintaining Connections with Stakeholders
MaxCyte acknowledges the importance of staying connected with its partners and stakeholders. They offer robust scientific, technical, and regulatory support to their partners, ensuring that they are well-equipped to manage the challenge of developing transformative therapies.
Contacting MaxCyte
For those interested in learning more about the company and its innovative work, MaxCyte's website offers comprehensive resources. Stakeholders can reach out through designated channels for investment or media inquiries, ensuring that communication flows smoothly as the company continues to grow.
Frequently Asked Questions
Who is Art Mandell?
Art Mandell is a former board member of MaxCyte, Inc., having served since 2006 and played a key role in the company's strategic direction and growth.
What are some of MaxCyte's achievements during Mandell's time on the Board?
Under Mandell’s oversight, MaxCyte accomplished its IPOs on the UK AIM and NASDAQ and launched its ExPERT™ platform, claiming numerous strategic licenses.
What is the ExPERT™ platform?
The ExPERT™ platform is a leading technology solution by MaxCyte, facilitating cell engineering processes and supporting the development of cell and gene therapies.
How can I contact MaxCyte for inquiries?
For inquiries, you can reach out to MaxCyte via email or their official website to get information on their operations and ongoing projects.
What does the future hold for MaxCyte after Mandell's retirement?
MaxCyte aims to continue its innovative path in cell engineering with strong leadership and remains committed to delivering revolutionary solutions in cell therapies.
